442 related articles for article (PubMed ID: 26367500)
1. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
[TBL] [Abstract][Full Text] [Related]
3. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
4. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
[TBL] [Abstract][Full Text] [Related]
5. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
7. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
[TBL] [Abstract][Full Text] [Related]
8. Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.
Kim CO; Cho SK; Oh ES; Park MS; Chung JY
J Cardiovasc Pharmacol; 2012 Jul; 60(1):49-54. PubMed ID: 22494992
[TBL] [Abstract][Full Text] [Related]
9. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
Keskitalo JE; Pasanen MK; Neuvonen PJ; Niemi M
Pharmacogenomics; 2009 Oct; 10(10):1617-24. PubMed ID: 19842935
[TBL] [Abstract][Full Text] [Related]
10. Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations.
Luzum JA; Theusch E; Taylor KD; Wang A; Sadee W; Binkley PF; Krauss RM; Medina MW; Kitzmiller JP
J Cardiovasc Pharmacol; 2015 Jul; 66(1):80-5. PubMed ID: 26164721
[TBL] [Abstract][Full Text] [Related]
11. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
[TBL] [Abstract][Full Text] [Related]
12. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
[TBL] [Abstract][Full Text] [Related]
13. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
[TBL] [Abstract][Full Text] [Related]
14. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
16. Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers.
Chen YR; Yu X; Xu LM; Mei J; Tian ML; Xu M; Jin QY; Ye LB; Yang SX
Xenobiotica; 2024 Jan; 54(1):38-44. PubMed ID: 38085693
[TBL] [Abstract][Full Text] [Related]
17. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
Ieiri I; Suwannakul S; Maeda K; Uchimaru H; Hashimoto K; Kimura M; Fujino H; Hirano M; Kusuhara H; Irie S; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2007 Nov; 82(5):541-7. PubMed ID: 17460607
[TBL] [Abstract][Full Text] [Related]
18. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
19. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]